• AAPL 169.3
  • TSLA 168.29
  • AMZN 179.62
  • MSFT 406.32
  • INTC 31.88
  • EURUSD 1.0699
Overview Fundamentals API Earnings EOD API Sample Code Pricing
Register now
Free trial

No credit cards required

Get free API key
  1. Supported exchanges /
  2. NASDAQ /
  3. INCY.NASDAQ

Incyte Corporation (INCY NASDAQ) stock market data APIs

$50.99 -0.69(-1.3%) as of April 26, 2024

Incyte Corporation Financial Data Overview

51.68
50.99
-
51.85
50.87
50.27-75.74
11 617 M
19.5245
225 M
3 696 M
1.06
0.672
Our easy-to-use no-coding solutions help you get the data effortlessly:
Excel Financial Add-In Google Sheets Financial Add-In Python
APIs SDK Windows Downloader

No long-term obligations. The minimum period is one month only. No wait. You get an API key with instructions in a few seconds right after subscription.

General: {
Code: 'INCY',
Type: 'Common Stock',
Name: 'Incyte Corporation',
Exchange: 'NASDAQ',
CurrencyCode: 'USD',
CurrencyName: 'US Dollar',
CurrencySymbol: '$',
CountryName: 'USA',
CountryISO: 'US',
OpenFigi: 'BBG000BNPSQ9',
ISIN: NULL,
CUSIP: NULL,
CIK: '879169',
EmployerIdNumber: '94-3136539',
FiscalYearEnd: 'December',
IPODate: '1993-11-04',
InternationalDomestic: 'Domestic',
Sector: 'Healthcare',
Industry: 'Biotechnology',
HomeCategory: 'Domestic',
IsDelisted: false,
}

Incyte Corporation Fundamental Data is available in our Financial Data APIs

  • Net Revenue 3 696 M
  • EBITDA 739 M
  • Earnings Per Share 2.65
  • Income Statements
  • Balance Sheets
  • Cash flows
Fundamental data package from $59.99 See full price
Get sample
of Fundamental API Data

Get Incyte Corporation Earnings via APIs

  • Latest Release 2024-03-11
  • EPS/Forecast 1.16

Get Incyte Corporation End-of-day Data via APIs

  • End of Day, Intraday and Live APIs
  • Splits
  • Dividends

Get Incyte Corporation latest news via APIs

Allogene Therapeutics (ALLO) Expected to Beat Earnings Estimates: Should You Buy?

Wall Street expects a year-over-year increase in earnings on lower revenues when Allogene Therapeutics (ALLO) reports results for the quarter ended March 2024. While this widely-known consensus outloo...

Incyte (INCY) Earnings Expected to Grow: Should You Buy?

Wall Street expects a year-over-year increase in earnings on higher revenues when Incyte (INCY) reports results for the quarter ended March 2024. While this widely-known consensus outlook is important...
Do you have any questions?
support@eodhistoricaldata.com